American Century Companies Inc. Buys 67,325 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

American Century Companies Inc. raised its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 12.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 612,616 shares of the company's stock after buying an additional 67,325 shares during the period. American Century Companies Inc. owned about 1.07% of Structure Therapeutics worth $16,614,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Bank of Montreal Can boosted its holdings in shares of Structure Therapeutics by 71.6% during the third quarter. Bank of Montreal Can now owns 46,502 shares of the company's stock worth $1,941,000 after purchasing an additional 19,408 shares during the period. FMR LLC lifted its holdings in Structure Therapeutics by 6.7% in the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company's stock worth $268,977,000 after buying an additional 383,635 shares during the period. Verition Fund Management LLC grew its position in shares of Structure Therapeutics by 15.3% in the 3rd quarter. Verition Fund Management LLC now owns 16,703 shares of the company's stock worth $733,000 after buying an additional 2,218 shares during the last quarter. Baker BROS. Advisors LP purchased a new position in shares of Structure Therapeutics during the third quarter valued at approximately $3,753,000. Finally, Cinctive Capital Management LP raised its holdings in shares of Structure Therapeutics by 111.0% during the third quarter. Cinctive Capital Management LP now owns 32,094 shares of the company's stock valued at $1,409,000 after acquiring an additional 16,883 shares in the last quarter. Institutional investors own 91.78% of the company's stock.

Remove Ads

Structure Therapeutics Stock Down 7.4 %

Shares of GPCR stock traded down $1.21 during trading hours on Friday, hitting $15.12. 949,763 shares of the company's stock traded hands, compared to its average volume of 861,983. The stock has a market cap of $867.03 million, a price-to-earnings ratio of -20.43 and a beta of -2.37. The stock's fifty day simple moving average is $23.03 and its two-hundred day simple moving average is $30.40. Structure Therapeutics Inc. has a 12-month low of $14.88 and a 12-month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. On average, equities analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on GPCR. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. William Blair initiated coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating on the stock. Finally, JMP Securities reissued a "market outperform" rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.